Clinical Trial Update: Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pucotenlimab in combination with MRG002 for HER2-positive cancer of unknown primary; study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary

Drugs mentioned

• MRG002
• Pucotenlimab

Snippet

Sponsor: Zhiguo Luo, MD, PhD | Conditions: Cancer of Unknown Primary | Phase 2 | Status: NOT_YET_RECRUITING